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ABSTRACT
The coronavirus disease-2019 (COVID-19) pandemic has profoundly changed clinical care and research, including the
conduct of clinical trials, and the clinical research ecosystem will need to adapt to this transformed environment. The
Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory and the Academic
Research Consortium, composed of academic investigators from the United States and Europe, patients, the U.S. Food
and Drug Administration, the National Institutes of Health, and industry members. A series of meetings were convened to
address the challenges caused by the COVID-19 pandemic, review options for maintaining or altering best practices, and
establish key recommendations for the conduct and analysis of clinical trials for cardiovascular disease and heart failure.
This paper summarizes the discussions and expert consensus recommendations. (J Am Coll Cardiol 2020;76:2368–78)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ISSN 0735-1097 https://doi.org/10.1016/j.jacc.2020.09.544
From the aInova Heart and Vascular Institute, Falls Church, Virginia; bDivision of Cardiovascular Medicine, The Ohio State
University, Columbus, Ohio; cDuke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina;
dUniversity of Cyprus Medical School, Shakolas Educational Center for Clinical Medicine, Nicosia, Cyprus; eHeart Failure and
Transplantation Section, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee; fSection of Cardiovascular Medicine, Yale
University School of Medicine, New Haven, Connecticut; gCardiovascular Division, Brigham and Women’s Hospital, Boston,
Massachusetts; hDepartment of Cardiology, Washington Veterans Affairs Medical Center, Washington, DC; iRobertson Institute of
Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow, United Kingdom; jCardiology Division,Massachusetts General
Hospital and Baim Institute for Clinical Research, Boston, Massachusetts; kSections on Cardiovascular Medicine and Geriatrics,
Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina; lDivision of Cardiovascular
Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland; mDivision of Cardiovascular Medicine, Stanford Uni-
versity, Palo Alto, California; nBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; oUnited
States Food and Drug Administration, Silver Spring, Maryland; pSection of Cardiology, San Francisco Veterans Affairs Medical
Center and School of Medicine, University of California-San Francisco, San Francisco, California; qPharmacy Practice Division,
Minneapolis VA Center for Care Delivery and Outcomes Research and University of Minnesota, Minneapolis, Minnesota; rDepart-
ment of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania; sStatistics Collaborative, Washington, DC; and the
tDivision of Cardiology andMetabolism, Department of Cardiology, Berlin-Brandenburg Center for Regenerative Therapies, German
Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany. The views expressed in
this paper are those of the authors and do not necessarily represent the views of the U.S. Food and Drug Administration or the U.S.
Department of Health and Human Services. P.K. Shah, MD served as Guest Editor-in-Chief for this paper.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’
institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information,
visit the JACC author instructions page.
Manuscript received June 22, 2020; revised manuscript received August 12, 2020, accepted September 9, 2020.
Listen to this manuscript’s
audio summary by
Editor-in-Chief
Dr. Valentin Fuster on
JACC.org.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 7 6 , N O . 2 0 , 2 0 2 0
ª 2 0 2 0 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E AM E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .
T he coronavirus disease-2019 (COVID-19)pandemic has dramatically altered healthcare delivery and clinical research world-
wide. Clinical trial activity apart from COVID-19
studies has plummeted. In April 2020, approximately
90% of clinical trial sites closed to enrollment world-
wide, with a 95% decline in cardiovascular trial activ-
ity (1,2). The rapid initiation of over 1,000 COVID-19
clinical trials contrasts with the decline in non–
COVID-19 research.
In response to these issues, regulators, sponsors,
and professional organizations including the U.S.
Food and Drug Administration (FDA), National In-
stitutes of Health (NIH), the European Medicines
Agency, and the European Society of Cardiology have
released guidance on the performance of clinical trials
in the era of COVID-19 (3–6). These statements pro-
mote the principles of safety for patients and research
team members while striving to preserve trial integ-
rity (7). Strategies to limit in-person data collection
and maintain physical distancing are suggested. In
response, trial telehealth and remote monitoring
protocol amendments have surged (8). Nevertheless,
although new regulatory and governmental guidance
documents may facilitate remote and electronic
data collection, specific methodologies and stan-
dardized practices have not been established (6,7).
The HF Collaboratory (HFC) is a multistakeholder
organization that seeks to improve evidence genera-
tion for new therapies, implementation of safe and
effective treatments, and clinical trial efficiency;
HFC includes patients, clinicians, clinical in-
vestigators, the FDA, NIH, industry, and payers (9).
The Heart Failure Academic Research Consortium
(HF-ARC) working group was convened through a
partnership between the HFC and ARC, with repre-
sentatives from the United States and Europe, to
develop a scientific expert statement of standardized
methods for heart failure (HF) clinical trials in
response to the COVID-19 pandemic.
GENERAL PRINCIPLES
The methods for adjudicating consensus are
described in the Supplemental Appendix,
Supplemental Figure 1, and Supplemental Table 1.
These recommendations focus largely on data
collection and analysis (3–5,7). Sponsors and regula-
tors must together decide which protocol procedures
can be safely and accurately completed and which
data are critical, and seek to maximize evidence
acquisition while embracing flexibility, including
protocol amendments and deviations when appro-
priate. When necessary, collection of imperfect data
is preferred to noncollection to minimize
difficulties with interpretability and statisti-
cal assessment arising from missing data.
Case report forms may require specific fields
for COVID-19–focused elements to facilitate
understanding of the pandemic’s impact,
including on enrollment, investigational
product delivery, follow-up completeness,
safety assessments, event rates, and to assist
clinical event committee adjudications (an
example can be found in the Supplemental
Appendix). Regional and country-specific
COVID-19 infection rates may also aid inter-
pretation of study results. To assure integrity
of the clinical trial, permanent changes to
study protocols, analysis plans, and informed
consents should be documented prospec-
tively, receive Institutional Review Board
approval, and be communicated to patients
(Central Illustration).
Ideally these activities will accelerate use of inno-
vative methodologies and digital tools by the clinical
trial ecosystem, acknowledging that individual
studies and research sites will react variably to local
disease burdens, resources, and institutional capa-
bilities (9). Additionally, although these suggestions
aim to reinvigorate clinical research during and
following the current pandemic, lasting trans-
formation and global stakeholder cooperation will be
needed to prepare for future events, including pro-
tocols for virtual screening, electronic consenting,
central institutional review boards, remote enroll-
ment, randomization, follow-up visits, site moni-
toring, endpoint ascertainment, and sample
collection, as well as statistical analysis plans to
handle mid-trial changes.
DATA AND TRIAL INTEGRITY
Typically, contract research organizations, sponsors,
and study staff engage in frequent queries of site data
to help prevent missingness, retain patients, and
identify protocol deviations. However, sponsors and
contract research organizations have increasingly
implemented remote monitoring during the
pandemic to collect data and ensure integrity with
adherence to Good Clinical Practice guidelines (10).
Typically, standardized direct counseling from
trained research staff encourages patients to adhere
to trial protocols, but remote pill counts may monitor
medication adherence and improve accountability at
lower cost than in-person visits (11). The stress and
mental health sequelae of the pandemic may require
increased attention to patient well-being and
AB BR E V I A T I O N S
AND ACRONYM S
AE = adverse event
COVID-19 = coronavirus
disease-2019
FDA = Food and Drug
Administration
HF = heart failure
HF-ARC = Heart Failure
Collaboratory–Academic
Research Consortium
HFC = HF Collaboratory
NYHA = New York Heart
Association
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counseling by trial personnel to ensure completion of
protocolled activities. Central statistical monitoring
may provide an alternative method to in-person site
visits (12). This technique searches for sites or regions
with data inconsistencies and may better identify
sites for audit. The integrity and timely delivery of
investigational pharmaceutical products to patients
and investigators has been affected by the pandemic,
and must also be proactively managed by
sponsors and regulators.
ENDPOINT COLLECTION
Digital and remote methods of endpoint ascertain-
ment have been suggested when possible (3–5,7).
Virtualization merits individual consideration for
each clinical trial, as the ability to acquire and analyze
these data depend on the patient population, inves-
tigational agent studied, and endpoints. Early and
direct communication with regulators is paramount to
agree on changes to trial design or analysis. Although
endpoints collectable only in a clinical setting, such
as cardiopulmonary exercise testing, may have to be
modified or delayed, others may be collected by alter-
native or remote methods on time. Decision-making is
influenced by trial characteristics and whether the
outcomes lie within the primary endpoints. As detailed
later in the text, alternative methods of assessment
often lack sufficient evidence of reliability compared
with established methodologies. Studies under devel-
opment should investigate at baseline the within-
patient agreement between in-clinic and remotely
obtained measurements to prepare for unforeseen
future challenges to study execution.
PATIENT-REPORTED OUTCOMES AND QUALITY-OF-LIFE
ASSESSMENTS. Patient-reported outcome (PRO) in-
struments have been extensively evaluated,
including for remote administration (13). The HF-
specific Kansas City Cardiomyopathy Questionnaire
(KCCQ) and Minnesota Living With Heart Failure
Questionnaire (MLHFQ) are both designated Medical
Device Development Tools by the FDA Center for
Devices and Radiological Health, and may be trans-
lated to digital or telephone formats from the original
self-administered paper (14,15). Anchoring these
PROs with patient global assessments (PGA) may
assist with establishing thresholds for meaningful
change (16). Nevertheless, collection of these end-
points using remote methodologies during the
pandemic, compared to prior, may increase within-
subject variability through environmental effects on
patient responses, coaching by assessors and family
or caregivers, and heightened susceptibility to
missing data. It also remains unclear whether data
from interviewer-based assessments can be pooled
with self-administered data. Thus, although imple-
mentation of remote PROs appears feasible, the
preferred collection method will depend on specifics
of the incorporating study and PRO instru-
ment (Table 1).
Few clinical trials independently assess dyspnea,
but it remains the most common multifactorial
patient-reported symptom in HF (17). Dyspnea is
often measured using Likert or visual analog scales.
The Likert is commonly assessed in paper format, but
may be done by telephone; the visual analog scale
requires a visual reference either on paper or a digital
monitor. Although the psychometric properties of
these methods have not been carefully evaluated,
interviewer and staff feedback are known to affect
patient responses, and selection of the appropriate
administration strategy is situationally dependent
(Table 1).
General health status PROs may be useful for pa-
tients with HF, separately or in combination with HF-
specific instruments (16). PGA captures the global
impact of disease and is one of the most widely used
PRO instruments in clinical trials (18). PGA does not
require baseline assessment as it incorporates com-
parison with a prior time point when asking whether
and how the patient’s overall status has changed,
though patients may interpret baseline differently
than investigators and recall may be imperfect. Like
dyspnea, PGA is commonly measured on a 7-point
Likert scale ranging from markedly better to mark-
edly worse, and can be assessed remotely and digi-
tally (19). The Short Form-36 (SF-36) and EQ-5D
questionnaires are other general PRO instruments
that have been used with paper collection, telephone
interview, and over the Internet. Among these, EQ-5D
may be preferred to SF-36 due to greater validation.
HIGHLIGHTS
 The COVID-19 pandemic has profoundly
affected patient care and the conduct of
clinical trials.
 HF-ARC scientific expert panel developed
recommendations for the conduct and
analysis of heart failure trials during the
pandemic.
 The HF-ARC consensus recommendations
support ongoing clinical trials and
strengthen the clinical trial ecosystem,
which should have sustained benefits in
the future.
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COVID-19 may impair PRO interpretation. Infec-
tion may worsen dyspnea and health-related qual-
ity of life, perhaps persistently; social distancing
and home lockdown may limit patient activities
that provoke breathlessness. The economic impact
and concerns for infection may affect mental health
and quality of life. Accordingly, PRO data during
COVID-19 may require statistical adjustment for
temporality and regionality, and contextualization
of the pandemic’s psychological burden, which may
be concurrently captured with disease-agnostic
PROs.
 When a PRO is assessed, the mode of administra-
tion should be recorded and similar scripts, in-
struments, and devices should be used before,
during, and after the pandemic, modifying only as
necessary to maximize data collection while
maintaining procedural integrity.
 PGA, EQ-5D, KCCQ, and MLHFQ are validated PROs
well-suited for HF trials employing remote study
visits, including those performed during the
COVID-19 pandemic.
 COVID-19 could influence PRO responses in com-
plex ways. Results should be interpreted in the
CENTRAL ILLUSTRATION Management of Coronavirus Disease-2019 Impact on Non–Coronavirus Disease-2019
Clinical Trials
Psotka, M.A. et al. J Am Coll Cardiol. 2020;76(20):2368–78.
Coronavirus disease-2019 (COVID-19) has globally affected clinical trial performance, patient behavior, and clinical care. Most clinical trial sites ceased site-based
enrollments and procedures; adverse event reporting declined for enrolled patients. Patient mobility declined in response to governmental orders and fear of
infection, and patient-care changes include widespread reductions in cardiovascular hospitalizations and increased numbers of at-home cardiac arrests, which may be
due to COVID-19 or cardiovascular conditions. We evaluate methods to promote valid remote endpoint ascertainment, adjudication of COVID-19 and non–COVID-19
events, and suggest considerations for careful statistical analysis plan and protocol alterations that may be made in consultation with regulators.
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context of regional timing and severity of the
pandemic, patient symptoms, and COVID-19
infection status, which may be assessed by sero-
logical status.
FUNCTIONAL AND EXERCISE MEASURES. New York
Heart Association (NYHA) functional classification is
widely used to assess functional status for patients
with HF (20). NYHA functional class can be collected
remotely by patient interview but may be affected by
environmental factors similarly to PROs. Objective
measurement of maximal or submaximal exercise
capacity requires equipment, and trials with short-
term hemodynamic or functional endpoints may be
temporarily suspended then restarted when the
pandemic is better controlled. Although cardiopul-
monary exercise testing and peak VO2 measurement
may not be possible remotely, there are established
strategies to collect accelerometer-based activity for
timed walking tests such as the 6-min walk test (21).
Validation studies have been published for 2 home
6-min walk test smartphone applications, however,
the remote capture of these data elements has limi-
tations due to measurement error, sometimes poor
device reliability, lack of performance testing, and
frequent missing data (21–24). In addition, patients
may need reminders to wear nonimplantable devices
to record their activity, the technology may have
psychological consequences that alter behavior, it is
unclear whether data from different modalities can be
pooled, and mask-wearing may affect performance
(25). Activity data from implantable devices may also
be used, but many of the technologies required to
capture these data may be differentially available in
the population. Finally, lifestyle changes with social
distancing may substantially reduce overall physical
activity and exertional tolerance, independent of
disease-related changes.
 Some exertional and functional testing measures
have digital remote options, but changes in
assessment method and variability associated with
remote data collection may add statistical noise.
 To facilitate analysis, it is best to record the mode
of test administration, modifying only as necessary
to maximize data collection while maintaining
procedural integrity.
 NYHA functional class may be remotely assessed
but the means of collection should be recorded and
its value to clinical trials should continue to be re-
examined.
IMAGING. Although remote use of many cardiac im-
aging modalities is infeasible, the growth of minia-
turized and portable echocardiographic platforms
could lessen the technological barriers to image
acquisition (26). Nonetheless, echocardiography has
been validated only with trained users, and patient-
acquired images are anticipated to be of variable
quality with missing data points. Although technician
home visits may be the option of highest quality, and
greatest expenditures, because of suboptimal posi-
tioning and privacy concerns, they face data collec-
tion and accuracy limitations. Thus, image
acquisition may be best delayed until it can be safely
performed in the health care setting.
TABLE 1 Advantages and Drawbacks of Remote Collection Strategies for PRO and Dyspnea Assessment
Strategy Advantages Drawbacks
Mail, paper  Consistent with validation
 Consistent with most trial operations
 Limited change to IRB/protocol/consent
 Remains self-administered
 Unobserved and nonproctored
 Relatively higher cost and inefficiency
 Inability to control missing data and response rate
 Inability to control interference from caregivers
Mail, paper, with
telephone script
 Consistent with most trial operations
 Ensures completion
 Limited change to IRB/protocol/consent





 Limited change to IRB/protocol/consent
 Proven track record in trials
 Ability to reduce missing data
 Potential influence from interviewer
 Less validated than paper form
 Requires confirmation that patient is the responder
Internet-based, digital  Similarity to paper form
 Ability to reduce missing data and inability to skip
response items with streamlined data transfer
 Used in clinical practice
 Immediate feedback
 Requires access to computer and Internet (biased)
 Requires IRB/protocol/consent modifications
 Cost required for site construction




 Similarity to paper form
 Ability to reduce missing data and inability to skip
response items with streamlined data transfer
 Used in prior research
 Immediate feedback
 Requires mobile phone service and data use (biased)
 Requires IRB/protocol/consent modifications
 Cost required for site construction
 Inability to control interference (bias or help) from
caregivers
IRB ¼ institutional review board; PRO ¼ patient-reported outcomes.
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 Multiple portable ultrasound-based data acquisi-
tion platforms are in use for clinical purposes;
however, remote echocardiographic assessment is
only validated with trained users.
 Technician home visits may be possible for small
studies, but require training and quality control by
a centralized core laboratory to ensure data
reliability.
BIOMARKERS. Biomarkers including troponin and
natriuretic peptides are commonly used for clinical
trial inclusion criteria, endpoints, event adjudication,
safety, and mechanistic evaluation or monitoring (27).
COVID-19 complicates biomarker use because infec-
tion is associated with increased circulating levels,
and they are risk markers for severe COVID-19 disease
and worse outcomes (28,29). Although in many cases,
biomarker changes appear to be due to noncardiac
critical illness, the COVID-19 coronavirus appears to
have tropism for the myocardium and vasculature
(30). Thus, COVID-19 complicates adjudication of
myocardial injury events and worsening HF events,
because the symptomatology and biomarkers may be
consistent with either COVID-19 or primary cardio-
vascular conditions (27,31). Additionally, biomarker
measurement and serum chemistries may not be
feasible due to site closures. Once accurate antibody
assays become available, stored biorepositories can
provide a more complete evaluation of known and
unknown COVID-19 infections in trial populations.
 Home-based biomarker and serum chemistry
testing may be leveraged as an option for patients
without obvious COVID-19; technical and inter-
pretation challenges for biomarkers remain, and
shared risk assessment and decision-making with
patients should determine which methodology for
safety laboratory assessment, if any, can be
achieved.
 Biosample collection for all clinical trial enrollees
may assist with adjudication and interpretation of
COVID-19–associated events.
HOSPITALIZATION AND MORTALITY ENDPOINTS.
Assessment of traditional clinical trial outcomes,
including emergency department visits, hospitaliza-
tions, and mortality, may be confounded by signs,
symptoms, and biomarkers of COVID-19 that overlap
with HF, increased overall death rates due to
COVID-19, direct myocardial injury with COVID-19,
and altered patient and clinician behavior from soci-
etal changes and governmental recommendations
(28,30). Patients with cardiovascular comorbidities
and HF appear to be at greater risk of more severe
COVID-19 disease in addition to an increased risk of
cardiovascular adverse events (32). Although overall
COVID-19 hospitalization and mortality rates remain
low and vary by geographic location, COVID-19
could contribute to the outcome in any individual
case, complicating event adjudication and
data interpretation.
TABLE 2 Competing Influences of COVID-19 on CV Event Rates
Effects on Events
Type of Event
Nonfatal CV Events Fatal CV Events
Reduction in event rates  Fear of hospitalization and contracting COVID-19 in
the inpatient setting (Y CV and HF hospitalizations,
Y myocardial infarctions)
 Hospitalization attributed to COVID-19 (Y CV and HF
hospitalizations, even with concurrent exacerbation)
 Decreased patient physical activity and provoked
symptoms (Y clinical visits and hospitalizations)
 Fear of hospitalization, reducing adjudication (Y CV and
HF deaths)
 Sicker patients may reside in skilled nursing facilities
with exposure to COVID-19 ([ COVID-19 deaths with
Y CV and HF deaths)
 Financial incentive to attribute death to COVID-19 in the
United States (Y CV and HF deaths)
 Potential increased adherence to CV therapies
(Y CV and HF fatal and nonfatal events)
Increase in event rates  COVID-19 infection & inflammation increases risk of
underlying HF exacerbation ([ CV and HF events
including [ myocardial infarctions)
 Increased thrombosis associated with COVID-19
([ CV events)
 COVID-19 increases risk of renal injury ([ renal injury)
 Delayed presentations to medical care ([ deaths)
 Concern that cardiovascular medications such as angiotensin system antagonists may increase risk for or worsen COVID-19
([ CV and HF events and [ CV and HF deaths)
 Inability to obtain therapies, including due to cost (due to loss of employment) or fear of contracting COVID-19 ([ CV events,
[ outpatient worsening HF events, [ CV and HF deaths)
Unclear effect on event rates  Overlapping biomarker or clinical profiles of HF and CV diseases with COVID-19 (Y or [ CV and HF events including
myocardial infarctions)
Increased missing events or
events of unknown cause
 Increased comingled events at home without documentation or reporting
 Decline or reassignment of study personnel with decreased source documentation and data collection
 Undiagnosed COVID-19
COPD ¼ chronic obstructive pulmonary disease; COVID-19 ¼ coronavirus disease-2019; CV ¼ cardiovascular; HF ¼ heart failure.
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Patient behavior has changed markedly in
response to fears of infection and to social
distancing measures enacted by local authorities,
leading to decreased medical care and altered
nonfatal event rates. In Italy and the United States,
the COVID-19 pandemic was temporally associated
with a 40% decrease in presentation for acute cor-
onary syndromes (33,34). Worldwide, HF hospitali-
zation rates have dropped up to 50% with regional
COVID-19 spread and governmental activity re-
strictions (35) (Supplemental References). Patients
may forego care to avoid contact with the medical
system. Alternatively, diminished rates of myocar-
dial infarction and HF hospitalization may be due to
misdiagnosis, fewer true events associated with
increased sedentary behavior, or outpatient treat-
ment of worsening HF. The consequences of the
complex interplay of individual and societal factors
on cardiovascular health and event rates remain
unclear in some cases (Table 2). Nevertheless,
decreased events may lengthen the follow-up
required to demonstrate efficacy, and given diffi-
culties ascertaining cause of death, hamper inter-
pretation of clinical trial results if fatal event rates
increase.
The effect of COVID-19 on patient behavior may
also lead to altered rates and misclassification of
fatal events. In Lombardy, Italy, during the first
40 days of the outbreak, there was an almost 60%
increase in out-of-hospital cardiac arrests compared
with the same time period the previous year (36).
These deaths rose contemporaneously with regional
infections, but of the excess, only 75% were sus-
pected or diagnosed with COVID-19, suggesting a
potential concomitant increase in non–COVID-19
mortality, possibly from avoidance of appropriate
medical care. However, deaths due to COVID-19 or
other noncardiovascular etiologies are unlikely to be
treatable with investigational HF therapies and may
dilute a treatment effect. In addition, with limited
data and documentation available for adjudication,
clinical events committees may be unable to deter-
mine the cause of death. This may be particularly
pertinent to out-of-hospital sudden death or events
of unknown etiology, which are frequently ascribed
to cardiovascular causes, but may be best pre-
specified as noncardiovascular or analyzed as part
of sensitivity analyses. Local COVID-19 infection
prevalence and mortality patterns may be needed to
allow proper adjudication of events, acknowledging
that patient deaths are often due to a combination
of concurrent illnesses, and that consistency in
adjudication is more crucial than complete
accuracy.
 Changes in cardiovascular event rates in response
to COVID-19, and the adjudication and analysis of
these events, will be complex (Table 2).
 For nonfatal and fatal events, information on
COVID-19 status at the time aids in adjudication
and analysis: specifically, whether the patient was
definitely positive for COVID-19, definitely nega-
tive, unknown but suspected positive, or unknown
and suspected negative.
 Prospective and retrospective collection of COVID-19
symptoms, infection status, and events, which may
include nucleic acid and serological testing, should
be performed to aid analysis and interpretation of
the data (see case report form in the Supplemental
Appendix).
 Clinical events committees should adjudicate
whether COVID-19 was uninvolved, contributory,
or the primary cause of cardiovascular and non-
cardiovascular events.
ADVERSE EVENTS. Behavioral and societal forces
decreasing are also likely to limit ascertainment of
adverse events (AEs). Typically, AEs are collected by
clinical chart review and patient report; thus,
decreased contact and chart review by monitors can
reduce ascertainment. Telephone or virtual visits that
include AE checklists may capture some of this in-
formation, but rely on access and may be more diffi-
cult for older and sicker patients (37). Traditional mail
may be more accessible but at greater cost and subject
to increased risk of missing data.
Nevertheless, there is general consensus that clin-
ical trials collect excessive AE information and the
pandemic presents an opportunity to reduce that
burden in consultation with regulators (38). The FDA
has suggested collecting more extensive AE data on a
limited sample of enrolled patients, or a more focused
symptom catalog on all subjects, to reduce the
recording of AEs unlikely to contribute new knowl-
edge about the risks of the intervention (38).
 Patient reporting of AEs can be accomplished
remotely by virtual visit or telephone and may be
streamlined with questionnaires or focused event
checklists.
 In consultation with regulators, selective safety
data collection may be acceptable when the in-
tervention’s safety profile is well-characterized, for
instance, on a subset of the enrolled population.
SOCIOECONOMIC DISPARITIES
Ample evidence shows that socioeconomic factors
affect the risk of exposure, transmission, and devel-
opment of severe COVID-19, with patients of
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traditionally disadvantaged backgrounds experi-
encing higher rates of disease exposure, contraction,
and critical illness. In New York, areas of the city with
greater poverty and composed of more ethnic and
racial minorities had increased rates of hospitaliza-
tion and death from COVID-19 than wealthier and
more homogenous regions after adjustment for pop-
ulation density (39). Furthermore, racial and ethnic
minorities had disproportionately increased rates of
death (40). In China, Italy, and the United States, the
pandemic has particularly affected older patients,
with more hospitalizations and higher rates of critical
illness and mortality (41). In the Campania region of
Italy, the drop in presentation of patients for acute
coronary syndromes was greater for elderly than for
younger patients, and more pronounced for women
than men (33). These disparities must be considered
in the context of clinical trial execution, because
COVID-19 exacerbates longstanding inequalities in
clinical trial participation for women, the elderly, and
minority populations; additional sponsor resources
may be needed to manage these differences (9). On
one hand, remote patient assessment may improve
inclusion of under-represented populations, particu-
larly those in rural areas with transportation or access
barriers. However, for those without telephone,
Internet, or mailing addresses, the disparity may
hamper participation. The differential effect on
outcomes may also merit consideration of prospec-
tively identified sensitivity analyses among socio-
economic and demographic groups to understand the
impact on overall treatment effect within a clinical
trial.
STATISTICAL CONSIDERATIONS
COVID-19 challenges the design, execution, and
analysis of clinical trials. Although statistical analysis
plans (SAP) were written following extensive negoti-
ations between statisticians, sponsors, investigators,
and regulators, the pandemic may require prospec-
tive SAP alterations to allow the collected data to best
answer the clinical questions under study. SAP revi-
sion is complicated and consequential, and should be
done and documented prospectively in concert with
regulators to help ensure integrity of the study and
analysis. Although sponsors, regulators, and in-
vestigators recognize that trials in early stages of
implementation face the greatest potential adverse
impact of the pandemic, appropriate adaptation and
targeted flexibility could allow these trials to succeed.
Statistical considerations may influence what data to
collect, given variable susceptibility to statistically
informative missing data and bias, and statistical
adjustment may allow data collected by altered
methods to be used. Furthermore, projection of




















The progression of a clinical trial from design to completion, color coded by proximity to database lock and analysis (dark green ¼ ready for
analysis; dark red ¼ inappropriate for analysis). This concept can help assess initiation and stopping decisions. For instance, given difficulties
with recruitment and enrollment, trials with fewer than approximately 20% of endpoints collected in the dark red period may consider
pausing initiation or recruitment in consultation with regulators, until COVID-19 has waned. Alternatively, trials with >80% of endpoints
collected in green, may recalculate their power and consider stopping the trial to avoid the consequences of COVID-19 on endpoint
ascertainment, adjudication, and statistical analysis plan (SAP) adjustment; with at least 80% of events collected, there may be only a
modest 10% decrement in statistical power. Trials with approximately 20% to 80% of endpoints collected need to consider how best to adapt
to the issues covered in this paper, including remote endpoint collection, methods to minimize missing data, and SAP modifications.
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statistical power on the basis of the number of
collected events, alterations in event rates, and
enrollee counts may inform sponsor and scientific
decisions surrounding initiating or pausing enroll-
ment, as well as potentially stopping the clinical trial
earlier than originally intended. We recommend
considering the following issues:
 For a time-to-event endpoint, the decision
regarding data censoring in response to the
pandemic needs to balance loss of statistical power
with confounding of inference caused by including
pandemic-affected data. For a trial that has
collected approximately 80% of its endpoints
before COVID-19, there may only be a small
decrement in statistical power, and censoring may
be favored; sponsors may consider stopping the
trial immediately and analyzing the data to avoid
the analytic and statistical complications of the
pandemic (Figure 1). Alternatively, creation of a
modified composite endpoint including only reli-
ably ascertained components may be used.
 If approximately 20% to 80% of endpoints have
been collected, endpoints may either need to be
modified or stratified on the basis of patient-
specific impact of the COVID-19 pandemic and the
feasibility of endpoint ascertainment. A new SAP
would specifically describe the analytic approach
for data missing because of COVID-19, which may
affect the primary outcome analysis or subsequent
sensitivity analyses.
 For a trial that has enrolled few patients or for
which few endpoints have been collected, sponsors
may consider either substantially revising the SAP,
or designing a new trial to begin after the COVID-19
pandemic has sufficiently waned, to account for
changes to the clinical trial ecosystem.
 Statistically accounting for the timeline and in-
tensity with which COVID-19 affected local or
regional clinical care and patient behavior could
help adjust for the comprehensive changes in
health care utilization and efficacy associated with
the COVID-19 pandemic, including increased
overall mortality rates, decreased health care uti-
lization, excess mortality due to COVID-19, and
potentially increased HF mortality rates. The
timeline and intensity of COVID-19 will vary by
country and region. Ongoing assessments of
COVID-19 impact will continue to refine these
plans.
 Methods for missing data analyses for continuous
outcomes include multiple imputation, imputation
of a surrogate, opposite arm mean imputation, and
linear mixed and tipping point models. Each of
these rely on distinct statistical assumptions that
are best prospectively identified and justified in
the SAP. The reasons data are missing cannot be
verified from the nonmissing data, thus distinct
approaches should be used as sensitivity analyses
to confirm treatment effects are unaltered by
different missingness postulations. No single
solution will apply to all studies affected by
COVID-19. Stakeholders including regulators will
likely use multiple coordinated assessments to
understand the data, and noninferiority trials may
be more challenging than superiority trials to
evaluate in the presence of missing data.
 Studies under development should prepare for
unexpected catastrophic events similar to this
pandemic by outlining in their SAP how to handle
such natural disasters.
CONCLUSIONS
The COVID-19 pandemic has profoundly changed
clinical care and research including the performance
and analysis of clinical trials. We have summarized
expert consensus recommendations for clinical trials;
these principles should also be incorporated into
contingency planning for future public health crises
and systemic disruptions, including potential resur-
gence of COVID-19, to allow more seamless continu-
ation of clinical research. Although some clinical
research programs may unfortunately be substan-
tially adversely affected by COVID-19, we hope our
suggestions will help salvage ongoing clinical inves-
tigation and strengthen the clinical trial environment
for the future.
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